Medical Design and Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe

Boehringer Ingelheim to present new data at ASCO annual meeting regarding its investigational compound afatinib in EGFR-mutation positive patients with advanced NSCLC

May 25, 2011 By Bio-Medicine.Org

RIDGEFIELD, Conn., May 25 /PRNewswire/ — Boehringer
Ingelheim Pharmaceuticals, Inc. will present new phase Ib data at
the 2011 American Society of Clinical Oncology (ASCO) annual
meeting in Chicago (June 3-7) that indicates combining its
investigational therapy afatinib (BIBW 2992) with cetuximab at the
maximum tested dose controlled disease in all (n=22) treated
epidermal growth factor receptor (EGFR)-mutation positive patients
with non-small cell lung cancer (NSCLC) who developed acquired
resistance to treatment with a reversible EGFR tyrosine kinase
inhibitor (TKI). Researchers observed a tumor size reduction of up
to 76 percent over a treatment period of up to five months.(1) The
most common drug-related adverse events were rash and diarrhea,
with three patients (11.5%) experiencing Grade 3 rash. Afatinib is
an orally-administered irreversible inhibitor of the erbB family of
receptor tyrosine kinases, specifically EGFR and HER2.  It is
in late-stage development in advanced NSCLC and breast cancer.

Boehringer Ingelheim and QIAGEN are pleased that ASCO and the
National Comprehensive Cancer Network (NCCN), two leading oncology
organizations, recently recommended EGFR mutation testing for
patients with metastatic or recurrent NSCLC.  These
recommendations underscore the importance of genetic tumor testing
to predict patient response to certain treatments, enabling
personalized healthcare.  Boehringer Ingelheim has partnered
with QIAGEN to develop a real-time polymerase chain reaction assay
(real-time PCR) companion diagnostic test for afatinib that, if
approved, could help physicians identify which patients may benefit
from EGFR-targeted therapies.

“The ASCO and NCCN EGFR mutation testing recommendations
reinforce the importance of identifying the appropriate NSCLC
patients for clinical trials,” said Christopher Corsico, M.D.,
M.P.H., Senior Vice President, Medicine and Regulatory, Boehringer
Ingelheim Pharmaceuticals, Inc. “

‘/>”/>

SOURCE

Related Articles Read More >

A photo of Capstan Medical's mitral valve implant, which uses nitinol.
Capstan Medical’s R&D head discusses the heart valve and robotics startup’s tech, engineering challenges and solutions, advice for others in medtech and how to join his team
An illustration of a neurosurgeon using a robotic endoscope to remove a brain tumor.
MDO Nitinol Innovation Special Report
A photo of Highridge Medical CEO Rebecca Whitney.
Highridge Medical is betting on this spine tech
A photo of the miniature Auxilium Biotechnologies implants made on the International Space Station.
Implants 3D-printed in space could enable nerve regeneration
“mdo
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest medical device business news, application and technology trends.

DeviceTalks Weekly

See More >

MDO Digital Edition

Digital Edition

Subscribe to Medical Design & Outsourcing. Bookmark, share and interact with the leading medical design engineering magazine today.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
DeviceTalks

DeviceTalks is a conversation among medical technology leaders. It's events, podcasts, webinars and one-on-one exchanges of ideas & insights.

DeviceTalks

New MedTech Resource

Medical Tubing

MassDevice

Mass Device

The Medical Device Business Journal. MassDevice is the leading medical device news business journal telling the stories of the devices that save lives.

Visit Website
MDO ad
Medical Design and Outsourcing
  • MassDevice
  • DeviceTalks
  • MedTech100 Index
  • Medical Tubing + Extrusion
  • Medical Design Sourcing
  • Drug Delivery Business News
  • Drug Discovery & Development
  • Pharmaceutical Processing World
  • R&D World
  • About Us/Contact
  • Advertise With Us
  • Subscribe to Print Magazine
  • Subscribe to our E-Newsletter
  • Listen to our Weekly Podcasts
  • Join our DeviceTalks Tuesdays Discussion

Copyright © 2025 WTWH Media, LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media LLC. Site Map | Privacy Policy | RSS

Search Medical Design & Outsourcing

  • Home
  • Medical Device Business
    • Mergers & Acquisitions
    • Financial
    • Regulatory
  • Applications
    • Cardiovascular
    • Devices
    • Imaging
    • Implantables
    • Medical Equipment
    • Orthopedic
    • Surgical
  • Technologies
    • Supplies and Components Index
    • Contract Manufacturing
    • Components
    • Electronics
    • Extrusions
    • Materials
    • Motion Control
    • Prototyping
    • Pumps
    • Tubing
  • MedTech Resources
    • Medtech Events in 2025
    • The 2024 Medtech Big 100
    • Medical Device Handbook
    • MedTech 100 Index
    • Subscribe to Print Magazine
    • DeviceTalks
    • Digital Editions
    • eBooks
    • Manufacturer Search
    • Podcasts
    • Print Subscription
    • Webinars / Digital Events
    • Whitepapers
    • Voices
    • Video
  • 2025 Leadership
    • 2024 Winners
    • 2023 Winners
    • 2022 Winners
    • 2021 Winners
  • Women in Medtech
  • Advertise
  • Subscribe